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Background: Patients with acute decompensated heart failure are prone to recurrent exacerbation leading to poor
quality of life when they do not respond to an optimal medical regimen. Due to the lack of linear positive
inotropy response to increasing preload in heart failure patients, increasing preload is associated with poor
outcomes. Partial occlusion of either IVC or SVC is a proposed novel treatment that can improve cardiac function
or quality of life by altering preload/pressure in heart failure (HF) patients unresponsive to diuretics.
Methods: PubMed, Ovid (MEDLINE), and Cochrane database we searched using the MeSH terms including “Su
perior vena cava occlusion,” “Inferior vena cava occlusion,” “Heart failure exacerbation.” The inclusion criteria
included studies that enrolled patients > 18 years with diagnosed NYHA II-IV HF with reduced ejection fraction
(HFrEF) on optimal medical treatment (OMT).
Results: The analysis involved two studies with 14 patients; the mean age was 64.4 ± 10 and 100% males. The
difference in the mean pulmonary pressures between pre-and-post VCO devices were 1.56 (95% CI 0.66–2.46, pvalue = 0.006). There was no heterogeneity among the study of mean pulmonary pressures. With the use of VC
occlusion devices, the mean difference in pulmonary artery systolic pressure decreased by 1.70 (95% CI
0.68–2.71, p-value = 0.001) (Fig. 1B). The heterogeneity of mean pressure was minimal 14%.
Conclusion: In conclusion, VCO can help decrease pulmonary pressure that can indirectly prevent heart failure
exacerbations and possibly hospitalization in this cohort of patients.

1. Introduction
Patients with acute decompensated heart failure are prone to
recurrent exacerbation leading to poor quality of life when they do not
respond to an optimal medical regimen. Preload volume is a vital
contributor to a heart failure exacerbation. The increase in preload is
associated with the stretching of myocardial fibers. Due to the lack of
linear positive inotropy response to increasing preload in heart failure
patients, increasing preload is associated with poor outcomes. Partial

occlusion of either IVC or SVC is a proposed novel treatment that can
improve cardiac function or quality of life by altering preload/pressure
in heart failure (HF) patients unresponsive to diuretics [1,2]. This
meta-analysis evaluates the degree of change in pressures with vena
cava occlusion in patients with heart failure.
2. Methods
PubMed, Ovid (MEDLINE), and Cochrane database we searched
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using the MeSH terms including “Superior vena cava occlusion,” “Infe
rior vena cava occlusion,” “Heart failure exacerbation.” The inclusion
criteria included studies that enrolled patients > 18 years with diag
nosed NYHA II-IV HF with reduced ejection fraction (HFrEF) on optimal
medical treatment (OMT). They underwent intermittent occlusion of
IVC or SVC in artificial or natural ways. The OMT included symptomatic
or mortality lowering doses of diuretics, angiotensin-converting enzyme
inhibitors (ACEIs), angiotensin receptor blockers (ARBs), and betablockers (BBs). The primary outcome was to evaluate the change in
pulmonary artery pressure as an indirect means of lowering the wors
ening of heart failure exacerbations.

4. Discussion
The non-invasive inferior vena cava occlusion by exercise is
reviewed by Kaiser et al. enrolled six patients that underwent particle
occlusion of IVC by exercise. The study found that mean pulmonary
artery pressures dropped significantly with occlusion with no additional
neurological or cardiovascular complications. The study found that IVC
obstruction lowers left ventricular filling pressure, decreasing cardiac
workload, and improving myocardial contractility [1]. Another study by
Kapur et al. used an SVC occlusion device called Precardia to occlude the
SVC [2] intermittently. Kapur et al. involved eight patients with HFrEF.
All patients underwent Precardia device SVC intermittent occlusion. In
this study, at 5 minutes follow-up, JVP promptly rose and returned to
baseline after cessation of the occlusion. While the occlusion signifi
cantly reduced the atrial and ventricular end-diastolic pressures in all
the patients, there was no change in mean arterial pressure (MAP) and
CO of these patients.
Additionally, none of the patients reported any adverse neurological
or cardiovascular sequelae immediately after the procedure. The po
tential concern is the impact of elevated jugular venous pressure.
However, after 1 week, follow-up divulged that none of the patients
developed cerebrovascular accident, myocardial infarction, neurologic
complications of thrombosis secondary to the procedure, demonstrating
a very low risk of grave post-procedural outcomes.
The results delineated by Kapur et al. depicted that partial VCO can
be a safe therapeutic procedure that can be efficaciously employed in
heart failure patients. The Kapur et al. study results were significant and
got expedited approval of the device by the USA’s food and drug
administration (FDA) [5]. These studies demonstrated that partial
reduction of left ventricular volume by reducing preload from invasive
or non-invasive VCO might have several advantages. Firstly, sustained
increased cardiac contractility potentially increases cardiac output.
Secondly, VCO reduces right ventricular pressure and volume overload
that can shift the interventricular septum towards the right ventricle,
increasing the LV capacitance and stroke volume [6]. Thirdly, elevated
central venous pressure is associated with systemic congestion associ
ated with impaired renal function and diuretic resistance [7]. Hence,
correcting systemic venous congestion promotes renal function and
improves diuretic responsiveness, thereby leading to earlier deconges
tion of patients with acute decompensated heart failure. To achieve
these benefits for a prolonged period, we need an intermittent device
occluding the vena cava. The choice of vena cava for device implanta
tion is also essential. However, it is not well discussed in the literature.
The study by Kapur et al. experimented in superior vena cava. Cerebral
hypoperfusion is a concern regarding SVC occlusion. Although there was

3. Results
The analysis involved two studies with 14 patients; the mean age was
64.4 ± 10 and 100% males. The difference in the mean pulmonary
pressures between pre-and-post VCO devices were 1.56 (95% CI
0.66–2.46, p-value = 0.006) (Fig. 1A). There was no heterogeneity
among the study of mean pulmonary pressures. With the use of VC oc
clusion devices, the mean difference in pulmonary artery systolic pres
sure decreased by 1.70 (95% CI 0.68–2.71, p-value = 0.001) (Fig. 1B).
The heterogeneity of mean pressure was minimal 14%.
Safety measures and adverse effects of IVC and SVC occlusion using
preCARDIA catheter were discussed in Kapur et al. Acute IVC occlusion
reduced left ventricular systolic and diastolic pressures, LV volumes,
cardiac output (CO), and systemic blood pressure; in contrast, SVC oc
clusion reduced LV diastolic pressure and volumes without affecting
cardiac output or systemic blood pressure. SVC therapy using pre
CARDIA was well tolerated with stable MAP and CO without evidence of
damage to SVC, lungs, heart, or brain. However, in one animal study,
spontaneous sinus bradycardia and hypotension were observed after 14
hours of SVC therapy, but no damage to SVC, RA, RV, brain, or lungs was
noted. A large anterior wall myocardial infarction due to LAD ischemia
and reperfusion injury was also documented at autopsy. However, in all
three animal studies in Kapur et al., SVC occlusion increased IJ pressure,
reduced RA, mean PA, PCWP pressure; CO remained stable. One po
tential concern is the impact of elevated jugular venous pressure on the
cerebral function, but no neurologic deficits were identified during or up
to 7 days of follow-up after SVC occlusion [1].
Quality assessment was done as per the “Cochrane systemic reviews”
method3. The quality of the studies was moderate—Table 1 and Table 2.
Readmissions with acute decompensated heart failure remains a concern
among patients with HFrEF [3,4].

Fig. 1. A) Showing mean pulmonary pressures pre- and post-vena cava occlusion device. B) Showing mean pulmonary artery systolic pressures.
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In conclusion, VCO can help decrease pulmonary pressure that can
indirectly prevent heart failure exacerbations and possibly hospitaliza
tion in this cohort of patients. Therefore, in patients with refractory
heart failure unresponsive to appropriate medical intervention, partial
VCO might be the way forward.
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5. Conclusion

Sources of funding

No of
patients

Age

no case of neurological impairment in the study by Kapur et al., the
study included only eight patients that are not adequate to assess the
safety.
On the other hand, the device implantation in Inferior vena cava
precludes two-third of blood supply and might lead to profound hypo
tension. It also increases pressure in the splanchnic and renal vein that
may lead to renal injury and reduces oral medications’ absorption. Still,
more studies are needed in this therapeutic strategy since it is a rela
tively novel approach.
Our study analyzed both studies to see the mean pressure difference
as an indirect effect on pulmonary congestion. The mean difference of
pulmonary pressures and mean systolic pressures between pre-and-post
VCO were 1.56 (95% CI 0.66–2.46, p-value = 0.006) and 1.70 (95% CI
0.68–2.71, p-value = 0.001), respectively. Given the drop of 1.70 mmHg
in PASP, mild clinical improvement in pulmonary hypertension, the
results are limited to see the long-term effect of this change. Neverthe
less, the study has several limitations. Kaiser et al. was published as
abstract, so baseline characteristics are not available. The power of the
study is very low for the generalization of results. The long-term
outcome of the procedure is yet to be evaluated, and the studies had a
very short follow up period. Since the study has shown promising pre
clinical results, more randomized trials with adequate follow-up are
needed to evaluate the treatment option better.

Registration of Research Studies
Name of the registry: NA.
Unique Identifying number or registration ID: NA.
Hyperlink to your specific registration (must be publicly accessible
and will be checked): NA.

Kaiser
2019
Kapur
2019

Guarantor
Study

Table 1
Baseline and procedural characteristics of the included studies.

Inotropes

Diuretics

Creatinine

SVC
diameter mm

PA systolic pressure
pre-occlusion

PA mean pressure
pre-occlusion

PA mean pressure
post-occlusion
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Table 2
Quality of Cross-Over Studies Involved in Cochrane Systematic Reviews. B. Quality assessment of the studies as per the modified tool for quality assessment for case
series.
Study

Appropriate cross
over design

Randomized
treatment

Carry over
effect

Unbiased
data

Allocation
concealment

Blinding

Incomplete
outcome data

Selective outcome
reporting

Other
bias

Kaiser
2019
Kapur
2019

Low

Low

Low

Low

Low

Low

Low

Low

unclear

Low

Unclear

Low

Low

Low

High

Low

Low

Unclear

123 St. Stephen’s Green.
Dublin 2, Ireland.
Talalalmas.almas@gmail.com
+353834212442.
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